AEPGX
Price
$62.89
Change
+$0.41 (+0.66%)
Updated
Jul 31 closing price
Net Assets
140.66B
PWJAX
Price
$34.81
Change
+$0.18 (+0.52%)
Updated
Jul 31 closing price
Net Assets
4.62B
Interact to see
Advertisement

AEPGX vs PWJAX

AEPGX vs PWJAX Comparison Chart in %
View a ticker or compare two or three
VS
AEPGX vs. PWJAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AEPGX is a Buy and PWJAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
AEPGX has more cash in the bank: 141B vs. PWJAX (4.62B). AEPGX pays higher dividends than PWJAX: AEPGX (2.56) vs PWJAX (0.01). AEPGX was incepted earlier than PWJAX: AEPGX (42 years) vs PWJAX (14 years). PWJAX (1.25) is less costly to investors than AEPGX (0.83). PWJAX is a more actively managed with annual turnover of: 81.00 vs. AEPGX (50.00). AEPGX (6%) and PWJAX (6%) have equivalent initial investment costs. AEPGX has a lower initial minimum investment than PWJAX: AEPGX (250) vs PWJAX (1000). AEPGX annual gain was more profitable for investors over the last year : 8.28 vs. PWJAX (4.73). AEPGX return over 5 years is better than : -3.18 vs. PWJAX (-6.06).
AEPGXPWJAXAEPGX / PWJAX
Total Expense Ratio0.831.0976%
Annual Report Gross Expense Ratio0.831.2566%
Fund Existence42 years14 years-
Gain YTD3.9332.654148%
Front Load6%6%105%
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets141B4.62B3,051%
Annual Yield % from dividends2.560.0126,501%
Returns for 1 year8.284.73175%
Returns for 3 years18.5428.9464%
Returns for 5 years-3.18-6.0652%
Returns for 10 years46.68174.3427%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REPX34.270.75
+2.24%
Riley Exploration Permian
ARBB4.070.04
+0.99%
ARB IOT Group Limited
LSBK17.170.04
+0.23%
Lake Shore Bancorp Inc
PPL35.21-0.35
-0.98%
PPL Corp
VKTX31.74-1.37
-4.14%
Viking Therapeutics